NCT05938712View on ClinicalTrials.gov

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Kidney Transplant Recipients
Interventions
DRUG

Dapagliflozin 10 MG

Semaglutide subcutaneous once weekly for 12 weeks.

DRUG

Semaglutide, 1.0 mg/mL

Dapagliflozin oral once daily for 12 weeks.

Trial Locations (1)

M5G 2N2

RECRUITING

Toronto General Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER